Nurix Therapeutics Inc.

10.47
-1.41 (-11.87%)
At close: Apr 01, 2025, 3:59 PM
10.30
-1.62%
Pre-market: Apr 02, 2025, 08:05 AM EDT

Nurix Therapeutics Statistics

Share Statistics

Nurix Therapeutics has 75.89M shares outstanding. The number of shares has increased by 17.92% in one year.

Shares Outstanding 75.89M
Shares Change (YoY) 17.92%
Shares Change (QoQ) 7.13%
Owned by Institutions (%) 99.99%
Shares Floating 74.38M
Failed to Deliver (FTD) Shares 10.96K
FTD / Avg. Volume 1.39%

Short Selling Information

The latest short interest is 10.87M, so 15.34% of the outstanding shares have been sold short.

Short Interest 10.87M
Short % of Shares Out 15.34%
Short % of Float 15.77%
Short Ratio (days to cover) 13.03

Valuation Ratios

The PE ratio is -7.67 and the forward PE ratio is -6.54. Nurix Therapeutics's PEG ratio is -0.88.

PE Ratio -7.67
Forward PE -6.54
PS Ratio 27.21
Forward PS 1.7
PB Ratio 2.82
P/FCF Ratio -8.16
PEG Ratio -0.88
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Nurix Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 6.46, with a Debt / Equity ratio of 0.05.

Current Ratio 6.46
Quick Ratio 6.46
Debt / Equity 0.05
Debt / EBITDA -0.13
Debt / FCF -0.16
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $190.73K
Profits Per Employee $-676.81K
Employee Count 286
Asset Turnover 0.08
Inventory Turnover n/a

Taxes

Income Tax 270K
Effective Tax Rate -0.14%

Stock Price Statistics

The stock price has increased by -29.54% in the last 52 weeks. The beta is 2.18, so Nurix Therapeutics's price volatility has been higher than the market average.

Beta 2.18
52-Week Price Change -29.54%
50-Day Moving Average 16.05
200-Day Moving Average 20.71
Relative Strength Index (RSI) 23.24
Average Volume (20 Days) 786.19K

Income Statement

In the last 12 months, Nurix Therapeutics had revenue of 54.55M and earned -193.57M in profits. Earnings per share was -2.88.

Revenue 54.55M
Gross Profit 54.55M
Operating Income -213.03M
Net Income -193.57M
EBITDA -213.03M
EBIT -213.03M
Earnings Per Share (EPS) -2.88
Full Income Statement

Balance Sheet

The company has 110M in cash and 28.3M in debt, giving a net cash position of 81.69M.

Cash & Cash Equivalents 110M
Total Debt 28.3M
Net Cash 81.69M
Retained Earnings -738.77M
Total Assets 669.34M
Working Capital 523.53M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -172.58M and capital expenditures -9.27M, giving a free cash flow of -181.86M.

Operating Cash Flow -172.58M
Capital Expenditures -9.27M
Free Cash Flow -181.86M
FCF Per Share -2.71
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -390.52% and -354.85%.

Gross Margin 100%
Operating Margin -390.52%
Pretax Margin -354.36%
Profit Margin -354.85%
EBITDA Margin -390.52%
EBIT Margin -390.52%
FCF Margin -333.38%

Dividends & Yields

NRIX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for NRIX is $35, which is 234.3% higher than the current price. The consensus rating is "Buy".

Price Target $35
Price Target Difference 234.3%
Analyst Consensus Buy
Analyst Count 17
Stock Forecasts

Scores

Altman Z-Score 1.77
Piotroski F-Score 4